Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-843
- Development stage
- Phase 3
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Intramuscular, Intravenous, Oral
01
Overview
CKD-843 is an investigational, long-lasting injectable formulation of dutasteride being developed by Chong Kun Dang Pharmaceutical for the treatment of androgenetic alopecia (male pattern baldness). It is administered via intramuscular (IM) injection, planned for every 3 months. Classified as a small molecule and a new molecular entity, CKD-843 acts as a 5-alpha reductase inhibitor. It has completed Phase 1 trials and, as of April 2025, is planning a Phase 3 trial in South Korea to evaluate its efficacy and safety.
- Other names
- CKD 843CKD843CKD-843CKD-843-RCKD843-RCKD 843-R
02
Targets
SRD5A (Steroid 5-alpha-reductase)
Beyond the preview
Go deeper on CKD-843.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-843.